Zyngenia

Develops monoclonal antibody (mAb)-based drugs to treat cancer, inflammation and autoimmune disorders

placeGaithersburg, Maryland, United States calendar_todayFounded 2008 groups6 employees language zyngenia.com

Registered entities

Innovation

5 patent families (3 granted) — focus: Chemistry & metallurgy; filing pace slowing. Cited 2,400 times.

YearFilings
20123
20133
20143
20151
20163
20173
20183
20192
20201
20212
20231

Investor mix

1 investor on record.

Investor typeCountShare
Venture capital1100%
Coming soon